MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of MLN9708 and vorinostat that can be given to patients with advanced solid
tumors. The safety of these drugs will also be studied.